iRhythm vs Novocure
iRhythm reported revenue of $747 million in fiscal 2025, about the same as Novocure's $655 million in fiscal 2025. iRhythm's revenue grew 26.2% in its latest year, and Novocure's grew 8.3%. iRhythm had an operating margin of -7.7%, against -23.5% at Novocure. Free cash flow was $35 million at iRhythm and −$76 million at Novocure.
Side by side
| iRhythm | Novocure | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $747M | $655M |
| Revenue growth | 26.2% | 8.3% |
| Revenue growth a year, last 5 years | 23.0% | 5.8% |
| Gross margin | 70.6% | 74.5% |
| Operating margin | −7.7% | −23.5% |
| Net margin | −6.0% | −20.8% |
| Free cash flow | $35M | −$76M |
| Free cash flow margin | 4.6% | −11.6% |
| Return on capital | −12.4% | −33.0% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 2.6% | 3.4% |
| Last close | $91.91 | $11.83 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $56,892, sold $22.7 million | sold $2.9 million |
| Piotroski F-score | 5 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
iRhythmNovocure
Operating margin
Percent of revenue
iRhythmNovocure
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
iRhythmNovocure